跳至主要内容
临床试验/NCT02808299
NCT02808299Unknown不适用

Liver Injury by Statins in Coronary Heart Disease (CHD) Patients With History of Hepatitis B Virus (HBV) Infection

The First Affiliated Hospital with Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2016年12月最近更新:
适应症

试验速览

阶段
不适用
入组人数
600
试验地点
1
主要终点
changes of alanine transaminase (ALT, U/L)

研究概览

简要总结

The purpose of this study is to investigate the incidence of liver injury by statins in coronary heart disease (CHD) patients with history of hepatitis B virus (HBV) infection.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • patients with CHD receive long-term statin treatment

排除标准

  • ALT is over ULN at baseline
  • infection of Hepatitis A Virus, Hepatitis C Virus or Hepatitis E Virus
  • triglyceride is over 4.5 mmol/L
  • decompensated liver cirrhosis (Child B or C)
  • active stage of HBV
  • infection of Burkitt's lymphoma virus or cytomegalovirus, or other acute infectious disease
  • congestive heart failure
  • malignant tumor
  • autoimmune disease
  • receive other potential hepatotoxicity drugs such as immunosuppressant, antituberculotic and non-steroid anti-inflammatory drug.

结局指标

主要结局

changes of alanine transaminase (ALT, U/L)

时间窗: one month, three months, six months

The peak increases of ALT from baseline to follow-up

number of participants with alanine transaminase (ALT) increasing over 3 folds of upper limit normally (ULN)

时间窗: one month, three months, six months

次要结局

  • number of participants with alanine transaminase (ALT) increasing over the ULN(one month, three months, six months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验